{"DataElement":{"publicId":"4761114","version":"1","preferredName":"Prior Therapeutic Procedure Palbociclib Everolimus Administered Stratification Type","preferredDefinition":"The stratification type related to the prior administration of palbociclib and/or everolimus.","longName":"PRIPALBOEVERTYPE","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"4761073","version":"1","preferredName":"Prior Therapeutic Procedure Palbociclib Everolimus Administered","preferredDefinition":"Information related to the prior administration of palbociclib and/or everolimus.","longName":"PRIPALBOEVER","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"3693401","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D743B17B-E51D-394C-E040-BB89AD4312FF","latestVersionIndicator":"Yes","beginDate":"2013-03-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2013-03-06","modifiedBy":"ONEDATA","dateModified":"2013-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4761071","version":"1","preferredName":"Palbociclib Everolimus Administered","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.:A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05):The act of having given something (e.g., a medication or test).","longName":"C49176:C48387:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1235D75D-CD25-3FA8-E050-BB89AD432922","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"ONEDATA","dateModified":"2015-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1235D75D-CD36-3FA8-E050-BB89AD432922","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4761091","version":"1","preferredName":"Prior Therapy Palbociclib Everolimus Stratification Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"PRIPALBOEVERTYPE","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No prior palbociclib and no prior everolimus","valueDescription":"No prior palbociclib and no prior everolimus","ValueMeaning":{"publicId":"4761092","version":"1","preferredName":"No prior palbociclib and no prior everolimus","longName":"4761092","preferredDefinition":"The non-affirmative response to a question.: Earlier in time or order.: An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The non-affirmative response to a question.: Earlier in time or order.: A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1235D75D-CD64-3FA8-E050-BB89AD432922","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1235D75D-CD7D-3FA8-E050-BB89AD432922","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"ONEDATA","dateModified":"2015-03-26","deletedIndicator":"No"},{"value":"Prior palbociclib or everolimus or both","valueDescription":"Prior palbociclib or everolimus or both","ValueMeaning":{"publicId":"4761093","version":"1","preferredName":"Prior palbociclib or everolimus or both","longName":"4761093","preferredDefinition":"Earlier in time or order.: An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05): An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: One and the other; relating to or being two in conjunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Both","conceptCode":"C49636","definition":"One and the other; relating to or being two in conjunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1235D75D-CD8E-3FA8-E050-BB89AD432922","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1235D75D-CDA7-3FA8-E050-BB89AD432922","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"ONEDATA","dateModified":"2015-03-26","deletedIndicator":"No"},{"value":"No prior CDK 4/6 inhibitor and no prior everolimus","valueDescription":"No Prior Cyclin-Dependent Kinase Inhibitor And No Prior Everolimus","ValueMeaning":{"publicId":"5236171","version":"1","preferredName":"No Prior Cyclin-Dependent Kinase Inhibitor And No Prior Everolimus","longName":"5236171","preferredDefinition":"The non-affirmative response to a question.: Earlier in time or order.: Any substance that inhibits cyclin-dependent kinase (CDK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell cycle regulation pathway. Inhibition of cyclin-dependent kinase results in cell cycle arrest and apoptosis.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The non-affirmative response to a question.: Earlier in time or order.: A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cyclin-Dependent Kinase Inhibitor","conceptCode":"C2185","definition":"Any substance that inhibits cyclin-dependent kinase (CDK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell cycle regulation pathway. Inhibition of cyclin-dependent kinase results in cell cycle arrest and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"317F65A1-06EA-F58A-E050-BB89AD433F1F","latestVersionIndicator":"Yes","beginDate":"2016-04-27","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"317F65A1-0703-F58A-E050-BB89AD433F1F","beginDate":"2016-04-27","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-27","modifiedBy":"ONEDATA","dateModified":"2016-04-27","deletedIndicator":"No"},{"value":"Prior CDK 4/6 inhibitor or everolimus or both","valueDescription":"Prior Cyclin-Dependent Kinase Inhibitor And/Or Everolimus","ValueMeaning":{"publicId":"5235713","version":"1","preferredName":"Prior Cyclin-Dependent Kinase Inhibitor And/Or Everolimus","longName":"5235713","preferredDefinition":"Earlier in time or order.: Any substance that inhibits cyclin-dependent kinase (CDK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell cycle regulation pathway. Inhibition of cyclin-dependent kinase results in cell cycle arrest and apoptosis.: Used to indicate that either or both of two items or options may be valid.: A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cyclin-Dependent Kinase Inhibitor","conceptCode":"C2185","definition":"Any substance that inhibits cyclin-dependent kinase (CDK), an enzyme that catalyzes the addition of a phosphate group to a protein in the cell cycle regulation pathway. Inhibition of cyclin-dependent kinase results in cell cycle arrest and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3177607E-5BDE-C289-E050-BB89AD437D49","latestVersionIndicator":"Yes","beginDate":"2016-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"317F65A1-0717-F58A-E050-BB89AD433F1F","beginDate":"2016-04-27","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2016-04-27","modifiedBy":"ONEDATA","dateModified":"2016-04-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1235D75D-CD48-3FA8-E050-BB89AD432922","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"ZIEGLERK","dateModified":"2016-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior palbociclib and/or ever","type":"Preferred Question Text","description":"Prior palbociclib and/or everolimus","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior CDK 4/6 inhibitor and/or everolimus","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"12375748-2A9F-8D8D-E050-BB89AD430CF5","latestVersionIndicator":"Yes","beginDate":"2015-03-26","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-03-26","modifiedBy":"ZIEGLERK","dateModified":"2016-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}